CLAIMS

1. Use of a pharmaceutical in the manufacture of a medicament for preventing and/or treating non-ischemic cardiomyopathy, wherein the pharmaceutical comprises:

dendritic cells obtained by a method comprising a step of culturing mononuclear cells in the presence of GM-CSF and IL-2 and a step of pulsing the cultured cells with α-galactosylceramide.

2. The use according to claim 1, wherein the non-ischemic cardiomyopathy is dilated cardiomyopathy or drug-induced cardiomyopathy caused by an anthracycline-based anticancer agent.

3. The use according to claim 1 or 2, further comprising an anthracycline-based anticancer agent.

4. The use according to any one of claims 1 to 3, wherein the pharmaceutical is for use in preventing and/or treating cardiomyopathy of a subject to whom an anthracycline-based anticancer agent has been administered.

5. Use of a pharmaceutical in the manufacture of a medicament for inhibiting a decrease in myocardial contractility, wherein the pharmaceutical comprises:

dendritic cells obtained by a method comprising a step of culturing mononuclear cells in the presence of GM-CSF and IL-2 and a step of pulsing the cultured cells with α-galactosylceramide.

6. Use of a pharmaceutical in the manufacture of a medicament for inhibiting or preventing myocardial cell death, wherein the pharmaceutical comprises:

dendritic cells obtained by a method comprising a step of

culturing mononuclear cells in the presence of GM-CSF and IL-2 and a step of pulsing the cultured cells with α-galactosylceramide.

7. Use of a pharmaceutical in the manufacture of a medicament for inhibiting or improving myocardial atrophy, wherein the pharmaceutical comprises:

dendritic cells obtained by a method comprising a step of culturing mononuclear cells in the presence of GM-CSF and IL-2 and a step of pulsing the cultured cells with α-galactosylceramide.

8. Use of a pharmaceutical in the manufacture of a medicament for progress-inhibiting and/or treating myocardial fibrosis, wherein the pharmaceutical comprises:

dendritic cells obtained by a method comprising a step of culturing mononuclear cells in the presence of GM-CSF and IL-2 and a step of pulsing the cultured cells with α-galactosylceramide.

9. A pharmaceutical for use as a medicament, wherein the pharmaceutical comprises:

dendritic cells obtained by a method comprising a step of culturing mononuclear cells in the presence of GM-CSF and IL-2 and a step of pulsing the cultured cells with α-galactosylceramide.